Green Antimicrobials as Therapeutic Agents for Diabetic Foot Ulcers.
Ines D TeixeiraEugénia CarvalhoErmelindo Carreira LealPublished in: Antibiotics (Basel, Switzerland) (2023)
Diabetic foot ulcers (DFU) are one of the most serious and devastating complications of diabetes and account for a significant decrease in quality of life and costly healthcare expenses worldwide. This condition affects around 15% of diabetic patients and is one of the leading causes of lower limb amputations. DFUs generally present poor clinical outcomes, mainly due to the impaired healing process and the elevated risk of microbial infections which leads to tissue damage. Nowadays, antimicrobial resistance poses a rising threat to global health, thus hampering DFU treatment and care. Faced with this reality, it is pivotal to find greener and less environmentally impactful alternatives for fighting these resistant microbes. Antimicrobial peptides are small molecules that play a crucial role in the innate immune system of the host and can be found in nature. Some of these molecules have shown broad-spectrum antimicrobial properties and wound-healing activity, making them good potential therapeutic compounds to treat DFUs. This review aims to describe antimicrobial peptides derived from green, eco-friendly processes that can be used as potential therapeutic compounds to treat DFUs, thereby granting a better quality of life to patients and their families while protecting our fundamental bio-resources.
Keyphrases
- antimicrobial resistance
- healthcare
- lower limb
- wound healing
- global health
- end stage renal disease
- ejection fraction
- immune response
- type diabetes
- newly diagnosed
- public health
- chronic kidney disease
- microbial community
- peritoneal dialysis
- oxidative stress
- staphylococcus aureus
- health insurance
- risk factors
- combination therapy
- adipose tissue
- skeletal muscle
- metabolic syndrome
- weight loss
- patient reported
- health information
- replacement therapy